Dow Jones Falls As Biden Taps Emergency Oil, Inflation Gauge Hits 39 Year High | Investor's Business Daily

2022-04-22 20:50:02 By : Admin

BREAKING: Dow Dives As Bears Maul Market On These Fears

The Dow Jones Industrial Average fell as President Joe Biden tapped the nation's emergency oil reserves amid spiraling prices. The Fed's favorite inflation gauge also spiked to the highest level since 1983. Cisco Systems (CSCO) was a top blue chip, while Leaderboard stock Vertex Pharmaceuticals (VRTX) gained on a positive pain treatment study.

Volume was mixed, rising on the New York Stock Exchange but falling on the Nasdaq according to preliminary data. Today marks the quarter- and month-end rebalancing by pension funds.

Meanwhile, the yield on the benchmark 10-year Treasury note fell about three basis points to 2.33%. Oil dipped sharply, with West Texas Intermediate crude falling 6.5% to around $101 per barrel.

Oil prices fell after President Biden moved to tap the nation's emergency supplies.

He unveiled his plan to release 1 million barrels per day from the Strategic Petroleum Reserve in a bid to cut spiraling gas prices. The reserve has typically been used for emergencies such as natural disasters.

The Democratic president's move comes as his party seems to be struggling heading into the midterm elections.

Biden blamed Vladimir Putin and the ongoing Russia-Ukraine war for forcing his hand. Global oil prices have spiked amid wide sanctions against Russia.

"Our family budgets, your family budgets to fill a tank, none of it should hinge on whether a dictator declares war," he said.

Meanwhile, the Federal Reserve's preferred inflation gauge spiked to levels last seen in the early 1980s.

The core personal consumption expenditures price index popped 5.4% compared to the same time last year, its biggest jump since 1983.

Jobless claims also rose last week to 202,000. This was higher than analyst expectations.

The Nasdaq fared best out of the major indexes, falling 1.5%. Chip giant Advanced Micro Devices (AMD) was one of the worst performers as it fell nearly 8.3%.

The S&P 500 was having slightly worse luck, dipping 1.6%. Etsy (ETSY) was among the worst laggards here as it fell 7.6%.

The S&P sectors were all negative. Utilities and consumer staples fared best while financials, communication services, technology and consumer discretionary were the worst laggards.

Small caps fared a bit better than the major indexes, the Russell 2000 closing down 1%.

Growth stocks were the best performers. Nevertheless, the Innovator IBD 50 ETF (FFTY), a bellwether for growth stocks, gave up 0.9%.

The Dow Jones Industrial Average had a painful end to the quarter. It fell about 550 points, or 1.6%.

Cisco stock was one of the better performers on the Dow Jones today, but still fell 0.5%.

Caterpillar (CAT) fared best with a 0.1% dip while Amgen (AMGN) skidded 0.3% lower.

Walgreens Boots Alliance (WBA) was the worst performer, dipping 5.6%. Intel (INTC) also struggled, falling 3.6%.

Vertex Pharmaceuticals was boosted on news that it conducted a successful middle-stage study on the VX-548 pain therapy.

This new treatment could be used as an alternative to opioids if it continues to make progress. The experimental drug could now enter late-stage testing later this year.

Vertex said a high dose of the drug provided significantly greater pain relief over the first two days after surgery than a placebo. Lower doses did yield a meaningful benefit vs. a placebo in the trials.

An alternative to opioids for acute pain is desirable due to their addictive qualities. Hundreds of thousands of Americans died amid the so-called opioid epidemic.

An estimated 40% of opioid overdose deaths involved a prescription opioid, according to the Department of Health and Human Services.

VRTX stock was one of the better performers in the stock market today with a 1.7% gain to 260.97. It rose higher in its buy zone from a 255.03 entry.

Vertex is a member of the prestigious IBD Leaderboard list of leading stocks. 

Recent IBD Stock of the Day Dutch Bros (BROS) is worth keeping on your watchlist for now.

It has slipped back below the cup-with-handle base's ideal entry point of 62.11. BROS is currently testing support at its short-term 10-day line, MarketSmith analysis shows.

If it can regroup and then rally back above this entry, then the consumer-spending play could offer a buying opportunity.

The firm saw same-store sales jump 10.1% in Q4 vs. the year-ago period. Analysts see adjusted EPS up 3% in 2022, before 60% growth in 2023, according to Zacks Investment Research.

The company is also investing heavily to drive further growth. Capital spending will range from $175 million to $200 million this year, including $15-$20 million for a new roasting facility to enable future growth.

Please follow Michael Larkin on Twitter at @IBD_MLarkin for more on growth stocks and analysis.

MarketSmith: Research, Charts, Data And Coaching All In One Place

These Are The 5 Best Stocks To Buy And Watch Now

This Is The Ultimate Warren Buffett Stock, But Should You Buy It?

Software Growth Stocks To Buy, Watch Or Sell

Stocks Fall Sharply, Oil Prices Plunge; Tesla, Jobs Loom

7:35 AM ET Several Dow Jones stocks move on earnings while the indexes struggle to regain strength after Jerome Powell's hawkish comments.

7:35 AM ET Several Dow Jones stocks move on earnings while the indexes...

Interest in ad-supported streaming video services is rising as subscription video-on-demand services like Netflix face slowing growth. (© Dave Cutler)

Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!

Get market updates, educational videos, webinars, and stock analysis.

Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.

Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.

*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.

Ownership data provided by Refinitiv and Estimates data provided by FactSet.

© 2000-2022 Investor's Business Daily, LLC. All rights reserved